SCHEMBL26145014

SCHEMBL26145014

COC(=O)c1cccc(S(=O)(=O)NC2CC(F)(F)C2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
LMNA P02545 4/20 0.55
KMT2A Q03164 2/20 0.52
KDM4E B2RXH2 1/20 0.49
ACLY P53396 2/20 0.47
HPGD P15428 1/20 0.47
SLC40A1 Q9NP59 1/20 0.46
USP2 O75604 1/20 0.45
KIF18A Q8NI77 1/20 0.43
TCF4 P15884 2/20 0.43
CTNNB1 P35222 2/20 0.43
POLB P06746 1/20 0.43
CTSG P08311 1/20 0.42
CMA1 P23946 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
LOX P28300 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26144921 0.86 ALDH1A1 (0.56) ALDH1A1LMNAKMT2AKDM4EUSP2
SCHEMBL28257095 0.85 ALDH1A1 (0.74) ALDH1A1LMNAKMT2AKDM4EACLY
SCHEMBL17479214 0.82 ALDH1A1 (0.76) ALDH1A1LMNAKMT2AKDM4EHPGD
SCHEMBL26144975 0.82 ALDH1A1 (0.51) ALDH1A1LMNAKMT2AKDM4EACLY
SCHEMBL17479352 0.82 ALDH1A1 (0.76) ALDH1A1LMNAKMT2AKDM4EHPGD
SCHEMBL26145012 0.81 ALDH1A1 (0.48) ALDH1A1LMNAKMT2AKDM4EACLY
SCHEMBL11278869 0.76 SLC40A1 (0.56) ALDH1A1KMT2AKDM4EACLYHPGD
SCHEMBL26998926 0.75 ALDH1A1 (0.50) ALDH1A1LMNAKMT2AKDM4EACLY
SCHEMBL3476507 0.75 TDP1 (0.60) ALDH1A1LMNAKMT2AKDM4EACLY
SCHEMBL29498636 0.75 KDM4E (0.47) ALDH1A1KMT2AKDM4ECA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240351984-A1 INDOLINE COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2024-10-24 US disclosed
US-12084420-B2 Indoline compounds for inhibiting KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2024-09-10 US disclosed
EP-4392407-A1 SPIRO INDOLINE INHIBITORS OF KIF18A Volastra Therapeutics, Inc. (US) 2024-07-03 EP disclosed
CN-118103352-A Spiroindoline inhibitors of KIF18A 沃拉斯查疗法公司 2024-05-28 CN disclosed
US-20230147507-A1 INDOLINE COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-05-11 US disclosed
US-20230147507-A1 INDOLINE COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-05-11 US disclosed
US-20230147507-A1 INDOLINE COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-05-11 US disclosed
WO-2023028564-A1 SPIRO INDOLINE INHIBITORS OF KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240351984-A1 INDOLINE COMPOUNDS FOR INHIBITING KIF18A KIF18A, KIF18B, KIF2C ALDH1A1 2609/4885LMNA 2893/4885KMT2A 339/4885
US-20230147507-A1 INDOLINE COMPOUNDS FOR INHIBITING KIF18A KIF18A, KIF18B, KIF2C ALDH1A1 2609/4885LMNA 2893/4885KMT2A 339/4885
US-12084420-B2 Indoline compounds for inhibiting KIF18A KIF18A, KIF18B, KIF2C ALDH1A1 2657/4885LMNA 2940/4885KMT2A 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.